[go: up one dir, main page]

SK284925B6 - Kombinovaný preparát a jeho použitie pri liečení neurodegeneratívnych ochorení - Google Patents

Kombinovaný preparát a jeho použitie pri liečení neurodegeneratívnych ochorení Download PDF

Info

Publication number
SK284925B6
SK284925B6 SK240-98A SK24098A SK284925B6 SK 284925 B6 SK284925 B6 SK 284925B6 SK 24098 A SK24098 A SK 24098A SK 284925 B6 SK284925 B6 SK 284925B6
Authority
SK
Slovakia
Prior art keywords
adenosine
ach
concentration
intracellular
muscarinic
Prior art date
Application number
SK240-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK24098A3 (en
Inventor
Hans-Peter Schubert
Hildegard Nimmesgern
Karl Rudolphi
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of SK24098A3 publication Critical patent/SK24098A3/sk
Publication of SK284925B6 publication Critical patent/SK284925B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SK240-98A 1997-02-26 1998-02-24 Kombinovaný preparát a jeho použitie pri liečení neurodegeneratívnych ochorení SK284925B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (2)

Publication Number Publication Date
SK24098A3 SK24098A3 (en) 1998-09-09
SK284925B6 true SK284925B6 (sk) 2006-02-02

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
SK240-98A SK284925B6 (sk) 1997-02-26 1998-02-24 Kombinovaný preparát a jeho použitie pri liečení neurodegeneratívnych ochorení

Country Status (30)

Country Link
US (1) US6037347A (et)
EP (1) EP0867192B1 (et)
JP (1) JP4374440B2 (et)
KR (1) KR100517186B1 (et)
CN (1) CN100363005C (et)
AR (1) AR011860A1 (et)
AT (1) ATE295738T1 (et)
AU (1) AU749278C (et)
BR (1) BR9800766A (et)
CA (1) CA2230350C (et)
CZ (1) CZ298367B6 (et)
DE (2) DE19707655A1 (et)
DK (1) DK0867192T3 (et)
EE (1) EE03387B1 (et)
ES (1) ES2242243T3 (et)
HR (1) HRP980097B1 (et)
HU (1) HUP9800396A3 (et)
ID (1) ID19941A (et)
IL (1) IL123453A (et)
MY (1) MY120530A (et)
NO (1) NO327200B1 (et)
NZ (1) NZ329839A (et)
PL (1) PL191576B1 (et)
PT (1) PT867192E (et)
RU (1) RU2194508C2 (et)
SI (1) SI0867192T1 (et)
SK (1) SK284925B6 (et)
TR (1) TR199800302A3 (et)
TW (1) TW590772B (et)
ZA (1) ZA981561B (et)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510683A (en) * 1998-10-01 2003-09-26 Novartis Ag Sustained release oral formulations of rivastigmine
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
AU5627398A (en) 1998-09-03
DE59812801D1 (de) 2005-06-23
TR199800302A2 (xx) 1998-09-21
NO980786D0 (no) 1998-02-25
JP4374440B2 (ja) 2009-12-02
AU749278B2 (en) 2002-06-20
CA2230350C (en) 2007-07-24
HRP980097A2 (en) 1998-12-31
DE19707655A1 (de) 1998-08-27
IL123453A (en) 2004-06-20
EP0867192A2 (de) 1998-09-30
HUP9800396A1 (hu) 1999-07-28
HU9800396D0 (en) 1998-04-28
NO980786L (no) 1998-08-27
ES2242243T3 (es) 2005-11-01
MY120530A (en) 2005-11-30
HRP980097B1 (en) 2006-09-30
NZ329839A (en) 2000-05-26
ZA981561B (en) 1998-08-26
RU2194508C2 (ru) 2002-12-20
PL325074A1 (en) 1998-08-31
AU749278C (en) 2003-07-31
EP0867192B1 (de) 2005-05-18
DK0867192T3 (da) 2005-09-05
CZ54098A3 (cs) 1998-09-16
EE03387B1 (et) 2001-04-16
PT867192E (pt) 2005-08-31
CN1192904A (zh) 1998-09-16
ATE295738T1 (de) 2005-06-15
CN100363005C (zh) 2008-01-23
EE9800075A (et) 1998-10-15
CA2230350A1 (en) 1998-08-26
KR19980071717A (ko) 1998-10-26
JPH10236979A (ja) 1998-09-08
PL191576B1 (pl) 2006-06-30
BR9800766A (pt) 1999-12-07
EP0867192A3 (de) 2000-12-06
TR199800302A3 (tr) 1998-09-21
SI0867192T1 (en) 2005-10-31
CZ298367B6 (cs) 2007-09-12
AR011860A1 (es) 2000-09-13
US6037347A (en) 2000-03-14
SK24098A3 (en) 1998-09-09
HUP9800396A3 (en) 2001-05-28
ID19941A (id) 1998-08-27
TW590772B (en) 2004-06-11
MX9801515A (es) 1998-08-30
KR100517186B1 (ko) 2005-12-05
IL123453A0 (en) 1998-09-24
NO327200B1 (no) 2009-05-11

Similar Documents

Publication Publication Date Title
DE60211343T2 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
US20150352107A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
JP7057075B2 (ja) 認知機能を改善するための方法および組成物
CN113923988B (zh) 取代的芳甲基脲和杂芳甲基脲、其类似物和使用其的方法
HRP960372A2 (en) (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate
AU2012321345B2 (en) Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
CZ6498A3 (cs) Použití rapamycinu a jeho derivátů v kombinaci s antagonistou NMDA a/nebo AMPA pro výrobu farmaceutických prostředků
SK284925B6 (sk) Kombinovaný preparát a jeho použitie pri liečení neurodegeneratívnych ochorení
JP2009525025A (ja) ニューロンニコチン受容体リガンドおよびその使用
HRP20040992A2 (en) Method for treating cognitive disorders
CZ298398A3 (cs) Farmaceutický přípravek
CN115515590A (zh) 马赛替尼用于治疗多发性硬化患者亚群
CN101155587A (zh) 毒蕈碱受体调节剂
JPH0623105B2 (ja) てんかんの発作の治療用製薬組成物
CA2168265C (en) Antidepressant
MXPA98001515A (en) Prepared combination for application in the demen
CA2416706C (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
EP1113803A1 (en) Antiviral combinations comprising lamivudine and abacavir
CZ7698A3 (cs) Nové spiro [2H-1-benzopyran-2,4´-piperidin] -4 (3H)-onové deriváty, jejich adiční soli s kyselinami a farmaceutické přípravky s jejich obsahem
JPH06305967A (ja) コリン作動性神経不全の改善・治療薬
EP0475844B1 (fr) Utilisation de N-(1-hexahydroazepinylalkyl) acétamides dans la préparation des médicaments destinés au traitement des troubles de la transmission cholinergique
Grünwald et al. The Effect of Calcium Antagonists in Experimental Atherosclerosis, the Underlying Cause of Heart and Cerebral Vascular Diseases
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
KR20110083324A (ko) 비타민 ｃ를 포함하는 태아의 신경세포 보호용 조성물
JP2010540640A (ja) ムスカリン作用性レセプターのモジュレーター

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100224